ZIOP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 Jan 2022 @ 00:00):

Stats
Today's Volume	2.13M
Average Volume	2.36M
Market Cap	208.12M
EPS	$0 ( 2022-02-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.07
ATR14	$0.104 (12.01%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-22	De Groot Eleanor	Sell	20 132	Common Stock
2021-03-04	Thistle Mary	Buy	150 000	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	37 500	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	5 000	Common Stock
2021-03-04	Buchi J Kevin	Buy	31 250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 95 transactions
Buy: 4 516 054 \| Sell: 1 683 458

Volume Correlation

Long: 0.25 (neutral)

Short: 0.41 (neutral)

Signal:(38.327) Neutral

ZIOPHARM Oncology Inc Correlation

10 Most Positive Correlations
JAGX	0.926
MICS	0.922
FCBC	0.92
ONEM	0.917
BWB	0.915
PSHG	0.914
CVBF	0.91
AROW	0.91
CYRN	0.908
BMRC	0.905

10 Most Negative Correlations
ITAQU	-0.963
MCAA	-0.954
OPRA	-0.945
RCEL	-0.941
COCO	-0.939
BRLI	-0.938
ARYD	-0.937
APTM	-0.935
SLAM	-0.935
TZPS	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ZIOPHARM Oncology Inc Correlation - Currency/Commodity

0.68
( moderate )

0.00
( neutral )

0.17
( neutral )

-0.29
( neutral )

-0.78
( moderate negative )

ZIOPHARM Oncology Inc Financials

Annual	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.380

Q3	2021
Revenue:	$398 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.110

Q2	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.110

Q1	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.100

Financial Reports:

No articles found.

ZIOPHARM Oncology Inc

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.